Finerenone
Brand names: Kerendia · Active ingredient: Finerenone
In short: Kerendia is indicated to: reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabet
What is Finerenone used for?
Kerendia is indicated to:
reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabetes mellitus (T2DM) .
reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes mellitus (T1DM) .
reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% .
Finerenone dosage
Measure serum potassium levels and eGFR before initiation. Do not initiate treatment if serum potassium is > 5.0 mEq/L .
The recommended starting dose of Kerendia is based on eGFR and is presented in Table 1.
eGFR (mL/min/1.73m2) | Starting Dose
≥ 60 | 20 mg orally once daily
≥ 25 to < 60 | 10 mg orally once daily
< 25 | Initiation is not recommended
For patients who are unable to swallow whole tablets, Kerendia may be crushed and mixed with water or soft foods such as applesauce immediately prior to use and administered orally .
CKD associated with T2DM or T1DM
The target daily dose of Kerendia is 20 mg orally.
Measure serum potassium 4 weeks after initiating treatment and adjust dose ; if serum potassium levels are > 4.8 to 5.0 mEq/L, initiation of Kerendia treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels . Measure serum potassium 4 weeks after a dose adjustment and periodically throughout treatment, and adjust the dose as needed .
Current Kerendia Dose
10 mg once daily | 20 mg once daily
Current Serum Potassium (mEq/L) | ≤ 4.8 | Increase the dose to 20 mg once daily.If eGFR has decreased by more than 30% compared to previous measurement, maintain 10 mg dose. | Maintain 20 mg once daily.
> 4.8 – 5.5 | Maintain 10 mg once daily. | Maintain 20 mg once daily.
> 5.5 | Withhold Kerendia. Consider restarting at 10 mg once daily when serum potassium ≤ 5.0 mEq/L. | Withhold Kerendia. Restart at 10 mg once daily when serum potassium ≤ 5.0 mEq/L.
Heart Failure with LVEF ≥ 40%
The target daily dose of Kerendia for heart failure (LVEF ≥ 40%) is dependent on renal function (eGFR) at initiation of Kerendia treatment .
The target daily dose is 40 mg orally once daily if eGFR at initiation is ≥ 60 mL/min/1.73m2.
The target daily dose is 20 mg orally once daily if eGFR at initiation is ≥ 25 to < 60 mL/min/1.73m2.
Measure serum potassium and eGFR 4 weeks after initiating treatment and adjust dose . Measure serum potassium and eGFR 4 weeks after a dose adjustment and monitor periodically throughout treatment, and adjust the dose as needed .
Current Kerendia Dose
10 mg once daily | 20 mg once daily | 40 mg once daily
Current Serum Potassium (mEq/L) | < 5.0 | Increase the dose to 20 mg once dailyIf eGFR has decreased by more than 30% compared to previous measurement, maintain current dose. | Maintain 20 mg once daily if eGFR < 60 mL/min/1.73m2 at initiation. Otherwise increase the dose to 40 mg once daily | Maintain 40 mg once daily.
≥ 5.0 to < 5.5 | Maintain current dose.
≥ 5.5 to < 6.0 | Withhold Kerendia. Restart at 10 mg once daily when serum potassium < 5.5 mEq/L. | Decrease to 10 mg once daily. | Decrease to 20 mg once daily.
≥ 6.0 | Withhold Kerendia. …
How to take Finerenone — instructions & advice from the label
Advise patients of the need for periodic monitoring of serum potassium levels. Advise patients receiving Kerendia to consult with their physician before using potassium supplements or salt substitutes containing potassium .
Advise patients to avoid strong or moderate CYP3A4 inducers and to find alternative medicinal products with no or weak potential to induce CYP3A4 .
Avoid concomitant intake of grapefruit or grapefruit juice as it is expected to increase the plasma concentration of finerenone .
Advise women that breastfeeding is not recommended at the time of treatment with Kerendia and for 1 day after treatment .
Warnings & precautions
Do not take this medicine if: Kerendia is contraindicated in patients:
Who are hypersensitive to any component of this product .
Who are receiving concomitant treatment with strong CYP3A4 inhibitors .
With adrenal insufficiency.
Kerendia can cause hyperkalemia .
The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with Kerendia and dose accordingly . Do not initiate Kerendia if serum potassium is > 5.0 mEq/L.
Measure serum potassium periodically during treatment with Kerendia and adjust dose accordingly . More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium .
Kerendia can cause worsening of renal function in patients with heart failure. Rarely, severe events associated with worsening renal function, including events requiring hospitalization, have been observed .
Measure eGFR in all patients before initiation of treatment or with dose titration of Kerendia and dose accordingly . Initiation of Kerendia in patients with heart failure and an eGFR <25 mL/min/1.73m2 is not recommended.
Measure eGFR periodically during maintenance treatment with Kerendia in patients with heart failure. Consider delaying up-titration or interrupting treatment with Kerendia in patients who develop clinically significant worsening of renal function.
Finerenone side effects
The following serious adverse reactions are discussed elsewhere in the labeling:
Hyperkalemia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
CKD associated with T2DM
The safety of Kerendia in patients with CKD associated with T2DM was evaluated in 2 randomized, double-blind, placebo-controlled, multicenter pivotal phase 3 studies, FIDELIO-DKD and FIGARO-DKD, in which a total of 6510 patients were treated with 10 or 20 mg once daily over a mean duration of 2.2 and 2.9 years, respectively.
Overall, serious adverse events occurred in 32% of patients receiving Kerendia and in 34% of patients receiving placebo in the FIDELIO-DKD study; the findings were similar in the FIGARO-DKD study. Permanent discontinuations due to adverse events also occurred in a similar proportion of patients in the two studies (6-7% of patients receiving Kerendia and in 5-6% of patients receiving placebo).
The most frequently reported (≥ 10%) adverse reaction was hyperkalemia . Hospitalization due to hyperkalemia for the Kerendia group was 0.9% vs 0.2% in the placebo group across both studies. Hyperkalemia led to permanent discontinuation of treatment in 1.7% receiving Kerendia versus 0.6% of patients receiving placebo across both studies. …
Drug interactions
Strong CYP3A4 Inhibitors
Kerendia is a CYP3A4 substrate. Concomitant use with a strong CYP3A4 inhibitor increases finerenone exposure , which may increase the risk of Kerendia adverse reactions. Concomitant use of Kerendia with strong CYP3A4 inhibitors is contraindicated . Avoid concomitant intake of grapefruit or grapefruit juice.
Moderate and Weak CYP3A4 Inhibitors
Kerendia is a CYP3A4 substrate. Concomitant use with a moderate or weak CYP3A4 inhibitor increases finerenone exposure , which may increase the risk of Kerendia adverse reactions. Monitor serum potassium during drug initiation or dosage adjustment of either Kerendia or the moderate or weak CYP3A4 inhibitor, and adjust Kerendia dosage as appropriate .
Strong and Moderate CYP3A4 Inducers
Kerendia is a CYP3A4 substrate. Concomitant use of Kerendia with a strong or moderate CYP3A4 inducer decreases finerenone exposure , which may reduce the efficacy of Kerendia. Avoid concomitant use of Kerendia with strong or moderate CYP3A4 inducers.
CYP2C8 Substrates
Kerendia is a weak CYP2C8 inhibitor at 40 mg. Kerendia increases exposure of CYP2C8 substrates at 40 mg dose , which may increase the risk of adverse reactions related to these substrates. …
About this medicine
Kerendia contains finerenone, a nonsteroidal mineralocorticoid receptor antagonist. Finerenone's chemical name is (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide. The molecular formula is C21H22N4O3 and the molecular weight is 378.43 g/mol. The structural formula is:
Finerenone is a white to yellow crystalline powder. It is practically insoluble in water; and sparingly soluble in 0.1 M HCl, ethanol, and acetone.
Each Kerendia tablet contains 10 mg, 20 mg, or 40 mg of finerenone. The inactive ingredients of Kerendia are lactose monohydrate, cellulose microcrystalline, croscarmellose sodium, hypromellose, magnesium stearate, and sodium lauryl sulfate. The film coating contains hypromellose, titanium dioxide and talc, in addition to ferric oxide red (10 mg and 40 mg strength tablets) or ferric oxide yellow (20 mg and 40 mg strength tablets).
How it works: Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fc726765-5d5a-4d6e-b037-b847bda9fb7c. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro